{
    "root": "303a7843-3037-ba17-e063-6294a90ae0f6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "celecoxib",
    "value": "20250313",
    "ingredients": [
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE",
            "code": "RFW2ET671P"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "68401960MK"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SHELLAC",
            "code": "MB5IUD6JUA"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "CELECOXIB",
            "code": "JCX84Q7J1L"
        }
    ],
    "indications": "celecoxib capsules indicated",
    "contraindications": "\u2022 lowest effective shortest duration consistent individual patient treatment goals ( 2.1 ) \u2022 oa : 200 mg daily 100 mg twice daily ( 2.2 , 14.1 ) \u2022 rheumatoid arthritis : 100 mg 200 mg twice daily ( 2.3 , 14.2 ) \u2022 jra : 50 mg twice daily patients 10 kg 25 kg . 100 mg twice daily patients 25 kg ( 2.4 , 14.3 ) \u2022 : 200 mg daily single dose 100 mg twice daily . effect observed 6 weeks , trial 400 mg ( single divided doses ) may benefit ( 2.5 , 14.4 ) \u2022 ap pd : 400 mg initially , followed 200 mg dose needed first day . subsequent days , 200 mg twice daily needed ( 2.6 , 14.5 ) hepatic impairment : reduce daily dose 50 % patients moderate hepatic impairment ( child-pugh class b ) . ( 2.7 , 8.6 , 12.3 ) poor metabolizers cyp2c9 substrates : consider dose reduction 50 % ( alternative management jra ) patients known suspected cyp2c9 poor metabolizers , ( 2.7 , 8.8 , 12.3 ) .",
    "warningsAndPrecautions": "celecoxib capsules 200 mg size ' 2 ' , white opaque cap , white opaque body 'c6 ' imprinted yellow band cap '200mg ' imprinted yellow band body available follows : ndc 43063-967-14 bottles 14 ndc 43063-967-30 bottles 30 ndc 43063-967-60 bottles 60 storage store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "\u2022 celecoxib capsules contraindicated following patients : known hypersensitivity ( e.g . , anaphylactic serious skin ) celecoxib , components product [ ( 5.7 , 5.9 ) ] . \u2022 history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids , reported patients [ ( 5.7 , 5.8 ) ] . \u2022 setting cabg surgery [ ( 5.1 ) ] . \u2022 patients demonstrated allergic-type sulfonamides [ ( 5.7 ) ] .",
    "indications_original": "Celecoxib capsules are indicated",
    "contraindications_original": "\u2022\u00a0Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals ( 2.1 ) \u2022\u00a0OA: 200 mg once daily or 100 mg twice daily ( 2.2 , 14.1 ) \u2022\u00a0RA: 100 mg\u00a0to 200 mg twice daily ( 2.3 , 14.2 ) \u2022\u00a0JRA: 50 mg twice daily in patients 10 kg to 25 kg. 100 mg twice daily in patients more than 25 kg ( 2.4 , 14.3 ) \u2022\u00a0AS: 200 mg once daily single dose or 100 mg twice daily. If no effect is observed after 6 weeks, a trial of 400 mg (single or divided doses) may be of benefit ( 2.5 , 14.4 ) \u2022\u00a0AP and PD: 400 mg initially, followed by 200 mg dose if needed on first day. On subsequent days, 200 mg twice daily as needed ( 2.6 , 14.5 ) Hepatic Impairment: Reduce daily dose by 50% in patients with moderate hepatic impairment (Child-Pugh Class B). ( 2.7 , 8.6 , 12.3 ) Poor Metabolizers of CYP2C9 Substrates: Consider a dose reduction by 50% (or alternative management for JRA) in patients who are known or suspected to be CYP2C9 poor metabolizers, ( 2.7, 8.8 , 12.3 ).",
    "warningsAndPrecautions_original": "Celecoxib Capsules 200 mg \n    Size '2', White opaque cap, white opaque body with 'C6' imprinted on the yellow band on the cap and '200mg' imprinted on the yellow band on the body and are available as follows:\n \n                  NDC 43063-967-14 Bottles of 14\n                  NDC 43063-967-30 Bottles of 30\n                  NDC 43063-967-60 Bottles of 60\n                  \n                     \n                        Storage \n    \n                        \n                     Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "\u2022\u00a0Celecoxib capsules are contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [\n \n  see Warnings and Precautions (\n  \n   5.7,\n  \n   5.9)\n \n  ]. \n    \u2022\u00a0History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs, have been reported in such patients [\n \n  see Warnings and Precautions (\n  \n   5.7,\n  \n   5.8)\n \n  ]. \n    \u2022\u00a0In the setting of CABG surgery [\n \n  see Warnings and Precautions (\n  \n   5.1)\n \n  ]. \n    \u2022\u00a0In patients who have demonstrated allergic-type reactions to sulfonamides [\n \n  see Warnings and Precautions (\n  \n   5.7)\n \n  ]."
}